Document Detail


Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada.
MedLine Citation:
PMID:  8877928     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To evaluate viscosupplementation with intraarticular hylan G-F 20 in current clinical practice. METHODS: A retrospective study of all patients with osteoarthritis of the knee treated with hylan by 5 Canadian clinicians over a period of 2.5 years. RESULTS: A total of 1537 injections were performed in 336 patients involving 458 knees. The overall response and the change of activity level were judged better or much better for 77 and 76% of the treated knees after the first course of treatment (3 weekly injections), and 87 and 84% after a 2nd course. The mean time elapsing between the first and 2nd course, 8.2 +/- 0.5 months, is an evaluation of the duration of benefits. Local adverse events were observed in 28 patients (32 knees), with an overall rate of 2.7% adverse events per injection, 7.0% per joint, and 8.3% per patient. No systemic adverse events were noted in any patient. The adverse events were characterized by pain and/or transient swelling of the injected joint, mostly mild or moderate in intensity, and 72% of the adverse events were considered to be possibly or probably related to the injection. The incidence of adverse events is significantly influenced by the injection technique: 5.2% adverse events per injection with a medial approach to a partially bent knee, and 2.4% (straight medial) and 1.5% (straight lateral). After an adverse event, clinical improvement still occurred in 69% of the affected knees. CONCLUSION: Hylan G-F 20 provided good clinical benefits and an acceptable safety profile in current clinical practice. The occurrence of adverse events after an intraarticular hylan injection is infrequent and unpredictable and is not necessarily hylan related, although injection related.
Authors:
A Lussier; A A Cividino; C A McFarlane; W P Olszynski; W J Potashner; R De Médicis
Related Documents :
7286798 - Tenography in de quervain's disease.
17804778 - Translaminar cervical epidural steroid injection: short-term results and factors influe...
12872788 - Treatment of blepharospasm with botulinum neurotoxin type a: long-term results.
21893668 - Psychogenic nonepileptic seizures in us veterans.
21207788 - Controlled, prospective, randomized, clinical evaluation of partial ceramic crowns inse...
21401538 - The effect of combining dexamethasone with ondansetron for nausea and vomiting associat...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of rheumatology     Volume:  23     ISSN:  0315-162X     ISO Abbreviation:  J. Rheumatol.     Publication Date:  1996 Sep 
Date Detail:
Created Date:  1997-01-16     Completed Date:  1997-01-16     Revised Date:  2008-02-01    
Medline Journal Info:
Nlm Unique ID:  7501984     Medline TA:  J Rheumatol     Country:  CANADA    
Other Details:
Languages:  eng     Pagination:  1579-85     Citation Subset:  IM    
Affiliation:
Rheumatic Disease Unit, Faculty of Medicine, Université de Sherbrooke, Québec, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Female
Humans
Hyaluronic Acid / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Injections, Intra-Articular
Knee Joint*
Male
Middle Aged
Osteoarthritis / drug therapy*
Retrospective Studies
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
125935-84-4/hylan; 9004-61-9/Hyaluronic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Risk factors for progression to new sites of radiographically defined osteoarthritis in women.
Next Document:  Coordinated regulation of hyaluronan and aggrecan content in the articular cartilage of immobilized ...